Fatigue Clinical Trial
Official title:
B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis
Primary Biliary Cirrhosis (PBC) is a liver disease that predominantly affects females, can
present for the first time at any age and which develops over many years. It is caused by
the immune system attacking the body's own tissues. People with PBC frequently experience
profound fatigue or tiredness which they liken to their "batteries running down" and
although people still want to undertake normal activities they often lack the energy to be
able to do them. This reduces quality of life, makes it difficult for people to work and can
end up with them becoming isolated in the community. At present the investigators have no
treatment for fatigue in PBC. Finding a treatment for fatigue in PBC is one of the highest
research priorities identified by patient groups.
The aim of this study is to undertake a clinical trial to examine the effects of a treatment
("Rituximab") on severe fatigue in PBC to help us understand whether this will be a
potentially useful treatment. The information that this will give us about how energy
generation changes in patients with PBC with and without the treatment will also help us to
develop new treatments for fatigue in other diseases. The study has the potential to improve
the quality of life of many patients with PBC, for whom there is currently no hope of
improvement.
The investigators will perform a randomised controlled study of Rituximab therapy in PBC
compared to placebo (1:1 ratio).
The study will be performed in a specialised clinical research environment at Clinical
Research Facility Royal Victoria Infirmary. The investigators have, for many years, worked
closely with PBC patient groups to focus on the problems that are important to our patients.
This study is fully supported by Liver North, a liver disease charity and patient support
group.
The study will take place over one year and will involve between 9 and 20 visits although a
number of these will be telephone visits. Blood tests and quality of life questionnaires
will be performed at the start of the study and after three, six, nine and twelve months. At
baseline and 12 weeks follow up physical activity will be monitored using monitors, and an
exercise test and MRI scan will be performed.
Primary Biliary Cirrhosis (PBC) is a liver disease that predominantly affects females, can
present for the first time at any age, and which develops over many years. It is caused by
the immune system attacking the body's own tissues. People with PBC frequently experience
profound fatigue or tiredness which they liken to their "batteries running down", and
although people still want to undertake normal activities they simply lack the energy to be
able to do them. This reduces quality of life, makes it difficult for people to work, and
can end up with them becoming isolated in the community. At present we have no treatment for
fatigue in PBC. Finding a treatment for fatigue in PBC is one of the highest research
priorities identified by patient groups.
We have shown that PBC patients with fatigue have an abnormality in the way they generate
energy within their muscles. This appears to be associated with the presence of an antibody
in the blood which is directed against an important protein which normal cells in the body
use to generate energy. In recent years new drug treatments have been developed which allow
us to safely suppress the part of the immune system which produces antibodies of the type
that seem to cause energy production problems in PBC. As yet, however, the extent to which
these medicines can improve fatigue through removal of antibodies in PBC has not been
tested.
The aim of this study is to undertake a clinical trial to examine the effects of this
treatment ("Rituximab") on severe fatigue in PBC to help us understand whether this will be
a potentially useful treatment. This will give us information about how energy generation
changes in patients with PBC and will also help us to develop new treatments for fatigue in
other diseases. The study has the potential to improve the quality of life of many patients
with PBC, for whom there is currently no licensed treatment.
We will perform a randomised controlled trial of Rituximab therapy in PBC compared to
placebo with the primary end point of fatigue severity. The study will be performed in a
specialised PBC clinical centre.
Our hypothesis is that the B-cell-directed immunotherapeutic agent Rituximab will improve
fatigue in PBC (an important and disabling symptom) through its effect on B-cells producing
antibodies which inhibit the function of pyruvate dehydrogenase (PDH) an important energy
generating enzyme.
Fatigue is a common and debilitating symptom which frequently impacts significantly on
quality of life and ability to function in patients with PBC. There are currently no
effective treatments for fatigue in PBC and new approaches are urgently required to address
this unmet need. Rituximab, a B-cell depleting agent, holds specific promise (with evidence
from a small-scale proof-of-concept pilot trial) as a therapy for fatigue in PBC, given the
strong evidence linking the antibody response to PDH in the pathogenesis of fatigue in this
disease. We also believe, given the robust diagnostic criteria and the availability of
validated clinical tools, that PBC is an important and useful human model in which to study
the pathogenesis and treatment of fatigue.
There are currently no treatments for fatigue in PBC and we are not aware of any other
treatments under evaluation.
A pilot study performed in Canada exploring the use of Rituximab in PBC (in 13 patients) has
provided proof-of-concept, showing that the agent is safe and well-tolerated in patients,
and is associated with a clinically significant reduction in fatigue. Fatigue severity was
assessed using the Fatigue Severity Scale (FSS) (potential range 9-63 points) with a fall
being seen from pre-treatment (median FSS=36, range 11-59) to post-treatment (median=29,
range 12-55). Taking into account the floor value for the FSS, this represents a median fall
in fatigue severity over 6 months of 26%. This compares with our own case-control study of
fatigue in PBC which suggests that fatigue severity in age and sex matched normal controls
is 30% lower than in PBC patients1 suggesting the potential for Rituximab therapy to return
PBC patients to close to normal with regards to their perceived fatigue. However, this pilot
study did not attempt to explore the mechanism of the effect, and since it did not use
severe fatigue as an inclusion criteria, the extent of possible improvement for such
patients is unclear; moreover, the study was not optimised for the study of fatigue (fatigue
was a secondary outcome and only some of the patients who participated had fatigue
potentially under-estimating the clinical effect). Patients showed a sustained reduction in
anti-PDH antibody levels of all isotypes, supporting the concept that Rituximab has a
beneficial effect on fatigue through depletion of PDH-reactive antibody.
The importance of severe fatigue in PBC and the current lack of treatments, the strong
theoretical basis for the approach, and the supportive pilot trial proof-of-concept data
all, we believe, justify a formal clinical trial of Rituximab targeting fatigue in PBC. Data
from animal models of PBC implicating activated B-cells in promoting autoreactivity, from
human in vitro studies showing increased TLR-mediated B-cell activation in PBC, from human
genetic studies showing disease associations with loci implicated in regulation of the
B-cell pool size and the pilot trial data showing improvement in liver biochemistry in PBC
patients treated with Rituximab all point to the potential for an additional, more generic
benefit for this treatment in terms of underlying liver inflammation further justifying a
substantive clinical trial in PBC.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04959214 -
The Effect Of Progressıve Relaxatıon Exercıses
|
N/A | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Completed |
NCT04531891 -
Utility and Validity of a High-intensity, Intermittent Exercise Protocol
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT04960865 -
Kinesio Taping and Calf Muscle Fatigue
|
N/A | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT06421233 -
The Effect of Endorphin Massage Applied to Postpartum Women on Anxiety and Fatigue Levels
|
N/A | |
Active, not recruiting |
NCT05344183 -
Immediate and Short-term Effects of Low-level Laser
|
N/A | |
Completed |
NCT04716049 -
Effectiveness of Recovery Protocols in Elite Professional Young Soccer Players
|
N/A | |
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05241405 -
Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast Cancer
|
N/A | |
Active, not recruiting |
NCT06074627 -
Radicle Energy2: A Study of Health and Wellness Products on Fatigue and Other Health Outcomes
|
N/A | |
Completed |
NCT03943212 -
The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis
|
N/A | |
Recruiting |
NCT05567653 -
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers
|
N/A | |
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT05863897 -
e-COGRAT: A Blended eHealth Intervention for Fatigue Following Acquired Brain Injury
|
N/A | |
Not yet recruiting |
NCT05002894 -
Effect of Pilates Exercises On Fatigue In Post Menopausal Women
|
N/A | |
Recruiting |
NCT04091789 -
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
|
Phase 2 | |
Completed |
NCT02911649 -
Reducing Sedentary Behaviour With Technology
|
N/A | |
Completed |
NCT03216616 -
Guided Self-Management Intervention Targeting Fatigue in Rheumatic Inflammatory Diseases
|
N/A |